| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $2.2M | -21.2% | -42.0% |
| SG&A Expense | $3.3M | +2.8% | +101.4% |
| Operating Income | -$5.5M | +8.3% | -1.5% |
| Net Income | -$5.4M | +9.1% | +9.4% |
| EPS (Basic) | -$0.25 | +16.7% | +54.5% |
| EPS (Diluted) | -$0.25 | +16.7% | +54.5% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $16.9M | +160.7% | +25.2% |
| Current Assets | $17.4M | +160.8% | +22.3% |
| Total Assets | $17.7M | +154.2% | +24.2% |
| Current Liabilities | $6.4M | -30.7% | -25.0% |
| Total Liabilities | $6.8M | -29.6% | -23.9% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$15.5M | — | — |
| Financing Cash Flow | $23.8M | — | — |
| $10.9M |
| +512.1% |
| +104.1% |